@FierceMedDev: Spiking costs blunt Covidien's strong sales quarter. News | Follow @FierceMedDev
@DamianFierce: Dx company LipoScience is going public, targeting a $40M IPO as $LPDX. Report | Follow @DamianFierce
> The global market for companion diagnostics will reach $19.3 billion by 2023, according to an analyst report. More
> Molecular diagnostic outfit Transgenomic has raised another $8.3 million in private placement financing, planning to speed the commercialization of its genetic tests. News
> Medtronic ($MDT) has picked up CE marks for its Complete SE stent, clearing the device for use in the superficial femoral arteries and proximal popliteal arteries. Item
> Stryker ($SYK) executives told investors that the company's pending $764 million buyout of Trauson Holdings is key to its future growth. Article
> Artemis Diagnostics is changing its name to Lightpoint Medical as it moves forward with a molecular imaging technology for cancer surgery. Release
Biotech News
@FierceBiotech: AstraZeneca kicks tires on respiratory program ditched by J&J. Story | Follow @FierceBiotech
@JohnCFierce: Cowen's Ed Nash is predicting '16 arrival of Sarepta's eteplirsen, with $263M start Question about accelerated OK. Personally I'm doubtful. | Follow @JohnCFierce
@RyanMFierce: IBM touts push into #biotech with bug-busting gel. Should we care yet? Report | Follow @RyanMFierce
> Celsion snags up to $100M Chinese pharma tie-up ahead of PhIII cancer data. Article
> What's in a drug name? Hopefully some Xzitement. News
Pharma News
@FiercePharma: Merrill Lynch high on Bayer: The company made its list of top Euro-stocks, thanks to new drugs/pipeline. More | Follow @FiercePharma
@AlisonBFierce: Feds OK Novavax's experimental flu vaccine program. News | Follow @AlisonBFierce
> Groups lobby White House as sunshine rule lingers. Report
> Novartis faces probes on Tekturna tactics, Iran sales. News